Antigenic epitope of Erns protein of swine fever virus, monoclonal antibody and application thereof
The CSFV Erns protein was sorted and expressed by the FACS method, and the monoclonal antibody 1M6F1 with strong specificity was identified and obtained, and its antigen epitope was recognized as 113-146 peptides, which solved the shortcomings in the research on CSFV Erns protein in the prior art and achieved the Efficient detection and diagnosis of swine fever virus.
Patent Information
- Application Number
- CN202410087827.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-22
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-01-22
AI Technical Summary
Research on antigen epitope of CSFV Erns protein in the prior art is relatively lacking, and efficient antibodies and detection methods are lacking, making it difficult to effectively identify and diagnose swine fever virus.
Mouse B cells were sorted by FACS method, heavy chain and light chain expression vectors were constructed, CHO cells were transiently transfected, CSFV Erns protein was purified and expressed, and a strong specific monoclonal antibody 1M6F1 was identified and obtained, and its antigen epitope was recognized as 113-146 peptides, used for IFA and Western blotting detection, and are used for vaccines and diagnosis.
The monoclonal antibodies specifically recognize CSFV Erns protein were successfully obtained, which achieved efficient antigen epitope identification and viral subtype recognition, and provided a high sensitivity method for detection and diagnosis of swine fever viruses.
Smart Images

Figure CN117886906B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biology, and in particular to an antigenic epitope of Erns protein of classical swine fever virus (CSFV), a monoclonal antibody and application thereof. Background Art
[0002] Classical swine fever (CSF) is caused by infection with CSF virus (CSFV), formerly known as hog cholera, and is one of the important viral infectious diseases of domestic pigs and wild boars. CSF is listed as a Class I animal infectious disease in my country and is highly contagious and pathogenic. CSF seriously endangers the healthy development of the global pig industry and is therefore listed as a reportable animal disease by the World Organization for Animal Health.
[0003] The CSFV genome is a single-stranded positive-strand RNA of approximately 12.3 kb in length, encoding a large open reading frame (ORF) with untranslated regions (UTRs) at both ends, and a 5'UTR and 3'UTR carrying an internal ribosome entry site. The ORF encodes a polyprotein that can be cleaved into four structural proteins (capsid protein C, envelope glycoprotein Erns, E1 and E2) and eight non-structural proteins (Npro, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B). Erns is an important structural protein of CSFV with good immunogenicity. It can stimulate the body to produce neutralizing antibodies and can be used as a target antigen for identifying CSFV infection and marking vaccine immune antibodies. At the same time, compared with the E2 gene, the coding sequence of the Erns gene is relatively conservative and can be used as a candidate target for antigen detection and diagnosis.
[0004] At present, the functional research of CSFV Erns protein mainly focuses on its influence on virus particle formation and virus replication, and there is still a lack of reports on Erns protein antigenic epitopes. The present invention uses FACS to sort single specific mouse B cells, and amplifies antibody sequences by in vitro reverse transcription and PCR, constructs heavy chain and light chain expression vectors and transiently transfects CHO cells, successfully obtains a monoclonal antibody, and identifies the antigenic epitope it recognizes, and finds that it specifically recognizes the 113-146 peptide segment of CSFVErns protein ( 113 TCRYDKNTDVNVVTQARNRPTTLTGCKKGKNFSF 146 ), and software analysis confirmed that the peptide sequence was conserved in different CSFV strains. The present invention uses single B cell amplification technology to recombinantly express a novel antibody against CSFV Erns protein with strong specificity and high titer, and identifies the specific epitope recognized by it, which lays a good foundation for further research on the function of CSFV Erns protein, the research on CSF vaccine and the establishment of a high-sensitivity detection method. Summary of the invention
[0005] The purpose of the present invention is to provide a sequence of a novel antibody against CSFV Erns protein, an antigenic epitope recognized and its use. The technical scheme of the method is: the CSFV Erns gene sequence is cloned into a pcDNA3.4 vector to construct a eukaryotic expression vector, CHO cells are transiently transfected, protein is purified through a downstream strep tag, the purified Erns protein is used as an antigen to immunize Balb / C mice, mouse spleen cells are separated, specific B cells are separated by FACS, and single B cell antibody variable region sequences are obtained by RT-PCR, heavy chain and light chain recombinant expression plasmids are constructed respectively, CHO suspension cells are transiently transfected, and a complete anti-CSFV Erns protein monoclonal antibody is expressed and purified by Protein G, and the antigenic epitope recognized by the antibody is identified.
[0006] Specifically, the present invention first provides an antigenic epitope of the CSFV Erns protein, wherein the antigenic epitope is a peptide segment 113-146 of the Erns protein, and its amino acid sequence is shown in SEQ ID NO:3 ( 113 TCRYDKNTDVNVVTQARNRPTTLTGCKKGKNFSF 146 ).
[0007] Furthermore, the present invention provides an antibody or an antigen-binding fragment thereof, which can specifically target the antigenic epitope of the above-mentioned CSFVErns protein, and the antibody is monoclonal.
[0008] Furthermore, the monoclonal antibody is 1M6F1 antibody, the amino acid sequence of its heavy chain variable region is shown in SEQ ID NO:1; the sequence of its light chain variable region is shown in SEQ ID NO:2.
[0009] Furthermore, the present invention provides a polynucleotide, characterized in that it encodes the above-mentioned antibody or antigen-binding fragment thereof.
[0010] Furthermore, the present invention provides an application of an antigenic epitope, an antibody or an antigen-binding fragment thereof, or a polynucleotide of a CSFV Erns protein in the preparation of a classical swine fever virus epitope vaccine antigen and a diagnostic reagent antigen.
[0011] Furthermore, the present invention provides an application of an antigenic epitope, an antibody or an antigen-binding fragment thereof, or a polynucleotide of a CSFV Erns protein in the detection of classical swine fever virus, wherein the application is for purposes other than disease treatment and diagnosis.
[0012] Beneficial Effects
[0013] The present invention obtains a monoclonal antibody that can specifically recognize CSFV Erns protein, and obtains the sequences of the heavy chain variable region and light chain variable region of the antibody. The monoclonal antibody can be used for IFA and Western blotting detection, and can well recognize CSFV Erns protein. Subtype identification shows that the heavy chain of the antibody subtype is IgG1 and the light chain is Kappa. By expressing the Erns protein in segments through a prokaryotic expression system and synthesizing a series of Erns protein short peptides, it is finally determined that the monoclonal antibody can specifically recognize the 113-146 peptide segment of the Erns protein, and the amino acid sequence it recognizes is 113 TCRYDKNTDVNVVTQARNRPTTLTGCKKGKNFSF 146 , as shown in SEQ ID NO:3. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 This is the electrophoresis diagram of PCR amplification of the CSFV Erns gene sequence fragment in Example 1 of the present invention. Among them, the first lane is the DNA standard DL2000 Plus, and the second lane is the CSFV Erns gene sequence fragment, indicating that the CSFV Erns fragment of the correct size was successfully obtained. The third lane is the pcDNA3.4-Erns-strep recombinant plasmid, which was identified by double restriction digestion of EcoR I / BamH I, and the expected vector fragment and gene fragment were obtained, indicating that the expression vector was constructed correctly.
[0015] Figure 2 It is the Coomassie brilliant blue staining identification after transient transfection of CHO cells with the pcDNA3.4-Erns-strep recombinant plasmid in Example 2. Among them, lane M is the protein molecular mass standard, lane 1 is the untransfected cell control, lanes 2 to 4 are cells collected after 1, 3, and 5 days of transfection, and lanes 5 to 7 are supernatants collected after 1, 3, and 5 days of transfection. The results show that the recombinant Erns protein is mainly expressed in the supernatant, and the expression amount gradually increases with the increase of transfection time. The band is clear and the size is about 40kDa, which is consistent with the expected size of the Erns protein.
[0016] Figure 3 The purified recombinant Erns protein in Example 2 was identified by Coomassie brilliant blue staining and Western blotting. Lane M is the protein molecular mass standard, lanes 1 and 2 are the purified Erns protein, and lane 3 is the blank control, indicating that the purified protein can react specifically with the strep tag antibody, the bands are clear, and it is the target protein of the correct size, which can be used as an antigen for immunization.
[0017] Figure 4The expressed recombinant antibody in Example 4 was subjected to SDS-PAGE electrophoresis and Coomassie Brilliant Blue staining for identification. Lane M is a protein molecular mass standard, lane 1 is a flow-through sample after binding with Protein G, lane 2 is a washed sample, and lanes 3-8 are eluted samples. The results show that the 1M6F1 antibody is purified and enriched to produce clear heavy and light chain bands of the correct size.
[0018] Figure 5 This is an IFA identification diagram of CSFV infected cells detected by 1M6F1 antibody in Example 5. The results show that the antibody can specifically recognize cells infected with SHIMEN and C strain viruses, producing red fluorescence, and at the same time, CSFV E2 antibody can also specifically recognize cells infected with SHIMEN and C strain viruses, producing green fluorescence.
[0019] Figure 6 This is a Western blotting identification diagram of using 1M6F1 antibody and β-actin internal reference antibody to detect CSFV infected cells 24h and 48h after infection in Example 5. The results show that the antibody can recognize CSFV Erns protein and produce specific bands.
[0020] Figure 7 This is a diagram for identifying the subtype of the 1M6F1 antibody in Example 5. The results show that the heavy chain of the antibody subtype is IgG1 and the light chain is Kappa.
[0021] Figure 8 This is a Western blotting identification diagram of the antigen epitope recognized by the 1M6F1 antibody in the preliminary segmented screening in Example 6. The results show that the peptide segments recognized by the antibody all contain 113 TCRYDKNTDVNVVTQARNRPTTLTGCKKGKNFSF 146 sequence.
[0022] Fig. 9 This is the ELISA identification diagram of the minimum antigen epitope in Example 6. The results show that the minimum epitope peptide segment recognized by the 1M6F1 antibody is 113 TCRYDKNTDVNVVTQARNRPTTLTGCKKGKNFSF 146 . DETAILED DESCRIPTION
[0023] In order to make the purpose, technical scheme and advantages of the present invention more clearly understood, the present invention is further described below in conjunction with specific embodiments. It should be understood that the following embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0024] Example 1 Construction of the recombinant eukaryotic expression vector pcDNA3.4-Erns-strep
[0025] The inventors first constructed the pCDNA3.4-Erns-strep eukaryotic expression plasmid and designed the primers as follows:
[0026] Erns-3.4-F: 5′-TGCTGATGGGTTGCGTAGCTGAAAATATAACTCAATGGAA-3′ (SEQ IDNO: 4)
[0027] Erns-3.4-R:5′-TTTTTCGAACTGCGGGTGGCTCCAGGCATAGGCACCAAACCAGG-3′(SEQID NO:5)
[0028] The above primers were all CSFV Erns-specific sequences after BLAST analysis, and the primers were synthesized by Shanghai Qingke Biotechnology Co., Ltd. The template was the Erns gene sequence of the CSFV Shimen strain (GenBank ID: AF092448.2) in the reference NCBI. After sequencing, it was completely consistent with the CSFV Erns gene sequence and was named pcDNA3.4-Erns-strep. The specific PCR reaction conditions were: pre-denaturation at 95°C, 3min; denaturation at 95°C, 30s; annealing at 56°C, 30s; extension at 72°C, 1min, and 30 cycles were set during the denaturation to extension process; final extension at 72°C, 10min. After electrophoresis, observe under ultraviolet light and take pictures. The synthesized plasmid was identified by PCR using the designed primers. After electrophoresis, it was observed under ultraviolet light, and a specific band of about 681bp was amplified ( Figure 1 ), the results are consistent with expectations.
[0029] Example 2 Transient transfection and protein purification of the recombinant eukaryotic expression vector pcDNA3.4-Erns-strep
[0030] The day before transfection, CHO cells were diluted to 3 × 10 6 cells / mL and maintained in suspension for 24 hours. On the day of transfection, count the CHO cells. If the survival rate is higher than 95%, continue transfection. Dilute the cells with fresh 37℃ preheated culture medium to a final density of 6×10 6 cells / mL. The transfection system was prepared based on a cell volume of 100 mL, using 4 mL of OptiPRO TM Dilute 100 μg of plasmid DNA in SFM and mix slowly; use 4 mL of Opti PRO TMDilute 100mg PEI transfection reagent with SFM and mix slowly. Add 4mL of diluted PEI to 4mL of diluted plasmid DNA. Slowly flip and mix, and incubate the complex at room temperature for 20 minutes. Slowly add the incubated complex to 100ml of cell suspension, place it in a 37℃, 8% CO2, 100r / min shaking incubator for suspension culture, add 600μL enhancer and 24mL auxiliary material after 18-22 hours, and continue to culture in the shaking incubator for 5 days. On the 1st, 3rd and 5th day after transfection, collect the supernatant and cell samples, respectively, perform SDS-PAGE electrophoresis and Coomassie Brilliant Blue staining to identify, and analyze the protein expression ( Figure 2 ). Then, strep beads were used to purify the target protein. The general process is as follows: the collected sample was incubated with pre-treated strep beads for 3 hours by shaking. The medium was washed with PBST containing 8.8g NaCl and 20mL 1MTris-HCl, and finally eluted with biotin, and the eluate was collected for Coomassie brilliant blue staining and Western blotting identification ( Figure 3 ).
[0031] Example 3 Animal Immunization
[0032] The purified Erns protein was used to immunize 5 4-week-old female Balb / C mice. Another group of 5 mice was used as a negative control. Before immunization, the concentration of the purified protein was determined. 50 μg of purified protein was mixed with MnJ (β) colloidal manganese adjuvant and immunized by intramuscular, subcutaneous, and intraperitoneal multi-point injection. The second immunization was performed 10 days after the first immunization, and the third and booster immunizations were performed 7 days later. The method and dosage refer to the first immunization.
[0033] Example 4 Sequence cloning and recombinant expression of CSFV Erns protein antibody
[0034] (1) Memory B cells were sorted using FACS.
[0035] Blood was collected from the eyeballs of the immunized mice, serum was taken as a positive control, and the mice were killed. The killed mice were soaked in 75% alcohol for 5 minutes, the mice were fixed, and the abdominal skin of the mice was gently cut with sterilized scissors. The spleen of the immunized mice was removed under sterile conditions and placed in a culture dish. A 40μm cell sieve was placed on a 50mL centrifuge tube, and the spleen was ground with a disposable grinding rod. DMEM was added to rinse the spleen, and the grinding solution was collected and centrifuged at 1000rpm for 5 minutes. Using the markers of mouse memory B cells, the cell population of memory B cells was marked by FACS analysis.
[0036] (2) Amplification and cloning of antibody variable region sequences
[0037] After the memory B cell population was isolated by FACS, it was sorted into a 96-well plate containing a lysis buffer to lyse the B cells and release the intracellular RNA. The antigen-specific single B cell antibody variable region gene sequence was obtained by reverse transcription, PCR and sequencing. After comparison with the NCBI gene library, the sequenced antibody heavy chain variable region sequence (SEQ ID NO: 6) and light chain variable region sequence (SEQ ID NO: 7) were cloned into the pcDNA3.4 vector containing the corresponding constant region.
[0038] (3) Recombinant expression of antigen-specific antibodies
[0039] The heavy chain plasmid DNA and light chain plasmid DNA were transiently transfected into suspended CHO cells at a ratio of 1:1 using PEI to recombinantly express antigen-specific antibodies. About 5 days after transfection, the cell supernatant was collected and the recombinant antibodies secreted and expressed in the supernatant were purified using Protein G beads. After centrifugation and filtration of the cell supernatant, it was combined with Protein G balanced on the column, impurities were washed with buffer, and the recombinant antibody was eluted with glycine at pH 2.5 and named 1M6F1. The expressed recombinant antibody was identified by SDS-PAGE electrophoresis and Coomassie Brilliant Blue staining to analyze the antibody expression ( Figure 4 ), the results showed that the 1M6F1 antibody was purified to produce clear heavy and light chain bands.
[0040] Example 5 Antibody specificity detection and subtype identification
[0041] To verify the specificity of the 1M6F1 antibody, cells were infected with the CSFV virulent strain (SHIMEN strain) and the vaccine strain (C strain) for 48 hours and then IFA was performed. At the same time, the CSFV E2 protein antibody was used as a control. The results showed that antibodies against E2 and Erns could recognize cells infected with the two virus strains and produce specific fluorescence ( Figure 5 ). At the same time, protein samples were collected 24h and 48h after the cells were infected with the virulent strain of CSFV (SHIMEN strain) for Western blotting analysis. The results showed that the 1M6F1 antibody could recognize a specific protein band with a molecular weight of about 40kDa, and the band was clear ( Figure 6 ). The antibody subtype was further identified using the Proteinech monoclonal antibody subtype identification kit. The results showed that the antibody subtype heavy chain was IgG1 and the light chain was Kappa ( Figure 7 ). Subsequently, the collected ascites was purified using Protein G, and the titer of the purified 1M6F1 antibody was detected by ELISA to be 1:512000.
[0042] Example 6 Identification of Antibody Recognition Epitopes
[0043] First, Erns (1-227aa) was divided into three segments (P1: 1-160aa; P2: 20-190aa; P3: 61-227aa), and expression plasmids were constructed according to the primers in Table 1 (SEQ ID NO: 8-13). The segmentation schematic diagram is shown in Figure 8 A. The PCR reaction conditions are: pre-denaturation at 95°C for 3min; denaturation at 95°C for 30s; annealing at 56°C for 30s; extension at 72°C for 45s, with 35 cycles from denaturation to extension; final extension at 72°C for 10min. The fragments were connected to the pCold-TF vector respectively, and positive clones were selected after transformation with BL21. Single colonies were selected for verification. After verification, expression was induced. The bacteria were cultured in a 37°C shaker until the OD value reached 0.6-0.8, and 1mM IPTG was added to induce expression. After induction at 16°C for 24h, the bacterial solution was collected for ultrasound. The results showed that the 1M6F1 antibody could react with the P1, P2, and P3 regions ( Figure 8 B), the overlapping regions of the three were further truncated and divided into three segments (P4: 61-160aa; P5: 61-140aa; P6: 108-160aa). According to the primers in Table 1 (SEQ ID NO: 14-19), amplification and induced expression identification were performed as described above. The results showed that the 1M6F1 antibody could react with both P4 and P6 regions ( Figure 8 C), the overlapping region of the two was further truncated and divided into three segments (P7: 108-145aa; P8: 108-150aa; P9: 115-150aa). According to the primers in Table 1 (SEQ ID NO: 20-25), amplification and induced expression identification were performed as described above. The results showed that the 1M6F1 antibody only reacted with the P8 region, indicating that the antigen epitope it recognized was located in the P8 region (108-150aa) ( Figure 8 D).
[0044] In order to further accurately identify the antigen epitope recognized by the 1M6F1 antibody, 7 different truncated peptides (SEQ ID NO: 3 and SEQ ID NO: 26-31) were synthesized by Jier Peptide Biological Co., Ltd., and the 7 peptides were used to coat the enzyme labeling plate for indirect ELISA identification. The results showed that the minimum epitope recognized by the 1M6F1 antibody for the Erns protein was a peptide segment of amino acids 113-146, and its sequence was 113 TCRYDKNTDVNVVTQARNRPTTLTGCKKGKNFSF 146 ( Fig. 9 ).
[0045] Table 1 Primer sequences used in the present invention
[0046]
[0047] In summary, the present invention provides a CHO cell expression, monoclonal antibody preparation, epitope identification and application for CSFV Erns coding protein. The CSFV Erns coding sequence is cloned into the pcDNA3.4 vector to construct a eukaryotic expression vector carrying a strep tag capable of expressing the CSFV Erns protein, transiently transfected into CHO suspension cells, and purified using the strep tag to obtain the CSFV Erns protein. Balb / C mice were immunized four times with the purified protein as an immunogen, mouse spleen cells were isolated, specific B cells were isolated, and the variable region sequence of a single B cell antibody was obtained by sequencing, and the complete anti-CSFV Erns protein monoclonal antibody was recombinantly expressed. The heavy chain of the antibody subtype is IgG1, and the light chain is Kappa. IFA and Western blotting analysis showed that the antibody can specifically recognize the CSFV Erns protein and can be used to detect Erns antigens under reducing conditions. The antigen epitope sequence it recognizes is 113 TCRYDKNTDVNVVTQARNRPTTLTGCKKGKNFSF 146 , further demonstrating the specificity of the antibody.
[0048] It should be understood that although the present invention has been described in detail above with general descriptions and specific embodiments, some modifications or improvements can be made on the basis of the present invention, which is obvious to those skilled in the art. Therefore, these modifications or improvements made on the basis of not departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.
Claims
1. A monoclonal antibody against CSFV Erns protein, characterized in that The monoclonal antibody is 1M6F1 antibody, the amino acid sequence of its heavy chain variable region is shown in SEQ ID NO:1; the sequence of its light chain variable region is shown in SEQ ID NO:
2.
2. A polynucleotide, characterized in that The polynucleotide encodes the monoclonal antibody according to claim 1.
3. Use of the monoclonal antibody against the CSFV Erns protein according to claim 1 or the polynucleotide according to claim 2 in the preparation of a detection reagent for classical swine fever virus.
